Aline Clavert
Aline Clavert is an expert in Hematology at Centre Hospitalier Universitaire d'Angers (France). Aline Clavert has authored 72 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 11 of them ongoing. SLR score: 378 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2010 - 2026
Number : 72
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
11 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations NCT07738887 — cells, administration, oral, safety, lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, tablets, leukemia, lymphoid, therapeutics, mutation, b-lymphocytes, epcoritamab | Phase 2 | Not yet recruiting | 2026 |
| A phase 3 multicenter randomised prospective open label trial of fixed duration (12 cycles) venetoclax obinutuzumab vs fixed duration (15 cycles) venetoclax pirtobrutinib vs MRD guided venetoclax pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18 MOIRAI) 2023-510294-34-00 — research design, lymphoma, leukemia, lymphocytic, chronic, b-cell, duration of therapy, leukemia, leukemia, lymphoid, therapeutics, random allocation | Phase 3 | Recruiting | 2025 |
| FILOCLL015 GLORIFY A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide doxorubicin vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY 2022-501554-11-00 — cells, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, rituximab, vincristine, histology, therapeutics, b-lymphocytes | Phase 2 | Recruiting | 2024 |
| A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab versus Lenalidomide plus Rituximab in patients With Relapsed Refractory (R R) Follicular Lymphoma Grade 1 to 3a or R R Marginal Zone Lymphoma 2023-504684-16-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics | Phase 3 | Active not recruiting | 2021 |
| FILOCLL14 STAIR Open label phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated CLL (STAIR) 2024-513936-80-00 — aged, therapeutics | Phase 2 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map